Novel approaches in the management of myeloma-related skeletal complications

G. Kesava Reddy, Tariq I. Mughal, G. David Roodman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-κB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initial studies have demonstrated that targeting RANK/RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer-related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1α, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are briefly described.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalSupportive Cancer Therapy
Volume4
Issue number1
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Multiple Myeloma
Bone Neoplasms
Bone Diseases
Diphosphonates
Neoplasm Metastasis
Macrophage Inflammatory Proteins
Osteoprotegerin
Spontaneous Fractures
Osteonecrosis
Chemokine Receptors
Interleukin-3
Hypercalcemia
Cytoplasmic and Nuclear Receptors
Neurologic Manifestations
Jaw
Renal Insufficiency
Monoclonal Antibodies
Ligands
Morbidity
Bone and Bones

Keywords

  • Denosumab
  • Interteukin-3
  • Macrophage inflammatory protein-1α
  • Osteoprotegerin
  • RANK
  • RANKL
  • Wnt signaling pathway

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology

Cite this

Novel approaches in the management of myeloma-related skeletal complications. / Reddy, G. Kesava; Mughal, Tariq I.; Roodman, G. David.

In: Supportive Cancer Therapy, Vol. 4, No. 1, 10.2006, p. 15-18.

Research output: Contribution to journalArticle

@article{ef086879cc5f4cdcb716f27cbeb47da2,
title = "Novel approaches in the management of myeloma-related skeletal complications",
abstract = "Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-κB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initial studies have demonstrated that targeting RANK/RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer-related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1α, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are briefly described.",
keywords = "Denosumab, Interteukin-3, Macrophage inflammatory protein-1α, Osteoprotegerin, RANK, RANKL, Wnt signaling pathway",
author = "Reddy, {G. Kesava} and Mughal, {Tariq I.} and Roodman, {G. David}",
year = "2006",
month = "10",
doi = "10.3816/SCT.2006.n.026",
language = "English (US)",
volume = "4",
pages = "15--18",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "1",

}

TY - JOUR

T1 - Novel approaches in the management of myeloma-related skeletal complications

AU - Reddy, G. Kesava

AU - Mughal, Tariq I.

AU - Roodman, G. David

PY - 2006/10

Y1 - 2006/10

N2 - Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-κB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initial studies have demonstrated that targeting RANK/RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer-related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1α, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are briefly described.

AB - Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-κB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initial studies have demonstrated that targeting RANK/RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer-related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1α, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are briefly described.

KW - Denosumab

KW - Interteukin-3

KW - Macrophage inflammatory protein-1α

KW - Osteoprotegerin

KW - RANK

KW - RANKL

KW - Wnt signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=33751167602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751167602&partnerID=8YFLogxK

U2 - 10.3816/SCT.2006.n.026

DO - 10.3816/SCT.2006.n.026

M3 - Article

VL - 4

SP - 15

EP - 18

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 1

ER -